In vivo cancer research using aggregation-induced emission organic nanoparticles

Drug Discov Today. 2017 Sep;22(9):1412-1420. doi: 10.1016/j.drudis.2017.04.004. Epub 2017 Apr 20.

Abstract

Exploration of a nanoplatform that benefits precise cancer diagnosis and treatment in vivo is particularly valuable. In recent years, aggregation-induced emission luminogens (AIEgens) have emerged as advanced fluorescent materials for the design and preparation of organic nanoparticles (NPs); they also have unique advantages in biomedical applications, especially in cancer diagnosis and theranostics. In this review, we summarize the current status of the development of AIEgen-based NPs for in vivo cancer research, including in vivo tumor diagnosis, drug delivery, and photodynamic therapy. We hope that our review will inspire more exciting research in cross-disciplinary fields, contributing to precise cancer diagnostics and therapeutics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Humans
  • Nanoparticles / administration & dosage*
  • Neoplasms / diagnostic imaging*
  • Neoplasms / drug therapy*
  • Optical Imaging
  • Theranostic Nanomedicine